Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | CBFB | Q13951 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | SI | P14410 | 2/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9356934 | 0.83 | HRH4 (0.44) | HRH4EGLN1CBFBMGAMGAA | |
| SCHEMBL24075056 | 0.82 | GRIN2B (0.54) | MGAMGAASIMGAM2PTGDR2 | |
| SCHEMBL24074300 | 0.80 | PARP1 (0.53) | MGAMGAASIMGAM2PTGDR2 | |
| SCHEMBL17276023 | 0.79 | HRH4 (0.42) | HRH4EGLN1 | |
| SCHEMBL8265189 | 0.79 | HRH4 (0.46) | HRH4EGLN1MGAMGAASI | |
| SCHEMBL31027971 | 0.79 | HDAC6 (0.52) | MGAMGAASIMGAM2PTGDR2 | |
| SCHEMBL22452223 | 0.79 | HDAC6 (0.52) | MGAMGAASIMGAM2PTGDR2 | |
| SCHEMBL17370973 | 0.79 | TCF4 (0.55) | MGAMGAASIMGAM2PTGDR2 | |
| SCHEMBL13141624 | 0.77 | NPC1 (0.53) | CBFBMGAMGAASIMGAM2 | |
| SCHEMBL23782320 | 0.75 | HRH4 (0.43) | HRH4EGLN1PTGDR2DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140100245-A1 | Antiviral Drugs for Treatment of Arenvirus Infection | SIGA TECHNOLOGIES, INC. (US) | 2014-04-10 | — | — | US | claimed |
| US-8623347-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-07 | — | — | US | claimed |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-02-03 | — | — | US | claimed |
| US-20140100245-A1 | Antiviral Drugs for Treatment of Arenvirus Infection | SIGA TECHNOLOGIES, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8623347-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623347-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623347-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140100245-A1 | Antiviral Drugs for Treatment of Arenvirus Infection | HAVCR2, ZC3HAV1, SARS1 | HRH4 1320/4885EGLN1 2808/4885CBFB 1223/4885 |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | ZC3HAV1, EIF2AK2, SARS1 | HRH4 2248/4885EGLN1 3088/4885CBFB 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.